mRNA COVID-19 vaccines induce superior immunoglobulin A titers in patients with cancer compared with viral vector vaccines: implications for immunization strategies by Yana Debie, Lise Verbruggen, Marc Peeters, Peter A. van Dam, Timon Vandamme

Get full text

The technology landscape for detection of DNA methylation in cancer liquid biopsies by Isabelle Neefs, Joe Ibrahim, Marc Peeters, Guy Van Camp, Ken Op de Beeck

Get full text

Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward by Konstantinos Papadimitriou, Georgios Antoniou, Christian Rolfo, Antonio Russo, Giuseppe Bronte, Vassilios Vassiliou, Demetris Papamichael, Marc Peeters, Panteleimon Kountourakis

Get full text

Single-Photon Emission Computed Tomographic Imaging of the Early Time Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl His-Annexin A5 in a Colorectal Cancer Xe... by Christel Vangestel, Christophe Van de Wiele, Gilles Mees, Koen Mertens, Steven Staelens, Chris Reutelingsperger, Patrick Pauwels, Nancy Van Damme, Marc Peeters

Get full text

Deep sequencing of the gene reveals a potential risk allele for non–small cell lung cancer and supports the negative prognostic value of variants by Christophe Deben, Jolien Van den Bossche, Nele Van Der Steen, Filip Lardon, An Wouters, Ken Op de Beeck, Christophe Hermans, Julie Jacobs, Marc Peeters, Guy Van Camp, Christian Rolfo, Vanessa Deschoolmeester, Patrick Pauwels

Get full text

Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. by Margot Geens, Sofie Stappers, Heleen Konings, Benedicte Y De Winter, Pol Specenier, Jan P Van Meerbeeck, Gert A Verpooten, Steven Abrams, Annelies Janssens, Marc Peeters, Paul Van de Heyning, Olivier M Vanderveken, Kristien J Ledeganck

Get full text

Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays by Christophe Deben, Edgar Cardenas De La Hoz, Felicia Rodrigues Fortes, Maxim Le Compte, Sofie Seghers, Steve Vanlanduit, Hendrik Vercammen, Bert Van Den Bogert, Nelson Dusetti, Abraham Lin, Geert Roeyen, Marc Peeters, Hans Prenen, Filip Lardon, Evelien Smits

Get full text

SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors by Pascal Hammel, Denis Smith, Pauline Afchain, Sophie Dominguez-Tinajero, Jean-François Seitz, Astrid Lievre, Eric Van Cutsem, Eric Assenat, Frédéric Di Fiore, Marc Peeters, Iradj Sobhani, Eric Raymond, Emilie Charton, Dewi Vernerey, Louis De Mestier, Catherine Lombard-Bohas

Get full text

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol by Suzanne Polinder, Ivan Borbath, Marc Peeters, Philippe Beutels, Elke Smits, Iris Verhaegen, Ella Roelant, Wouter Dercksen, Stella Heemskerk, Siddharth Chhajlani, Jelka Kuiper, Christophe M Deroose, Isolde Van der Massen, Annemiek Walenkamp, Wouter W de Herder, Johannes Hofland, Timon Vandamme

Get full text

Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients by Yana Debie, Irene Garcia-Fogeda, Lander Willem, Ella Roelant, Lise Verbruggen, Greetje Vanhoutte, Lieselot Croes, Christof Vulsteke, Wim Demey, Willem Lybaert, Marianne Hanssens, Alain Bols, Johan Van ongeval, Ann De Becker, Hilde Jansens, Maria E. Goossens, Annelies Janssens, Hans Prenen, Sébastien Anguille, Marc Peeters, Peter A. van Dam, Niel Hens, Steven Abrams, Timon Vandamme

Get full text

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers by Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

Get full text

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

Get full text